Kidney disease is either a cause, associated with or contributes to the acceleration of other comorbid conditions.
COVID-19 affects many tissues and organs due to its entry into cells via the ACE2 receptor (1, 2). Renal damage and loss of function have been observed from asymptomatic to ICU patients. Although the impact on other organs is much more noticeable: reduced lung capacity, myocarditis, vascular damage and brain fog; renal damage is far more hidden, with the true consequences not revealed until decades later (3, 4, 5).
We are already seeing a rise in renal disease due to the obesity and diabetes epidemics. We will now see even more due to a population that has been infected by a virus that evidently causes renal damage (3, 4, 5).
This talk will explore the many ways kidney dysfunction can play a role in advancing many diseases and cause dysfunction in other organs. You will learn how to identify patients most at risk of developing end stage renal disease, and most importantly explore strategies to prevent renal disease progression.
Topics covered include:
- Relationship between COVID-19 and renal disease.
- Why we should care more about renal disease and how to spot a patient at risk.
- How renal disease contributes to other comorbid conditions.
- Lifestyle and nutritional interventions to support chronic kidney disease patients.
Join Dr Michael Osiecki, the Managing Director of Bio Concepts, in this month’s webinar ‘The Rise of Renal Disease in the COVID Endemic World’.
Proudly presented by
acnem Members receive monthly webinars for FREE located in the Member Resources page! Join acnem today!
- Self WH, Shotwell MS, Gibbs KW, et al. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA. 2023;329(14):1170–1182. doi:10.1001/jama.2023.3546
- Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, Kesharwani P, Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021 Dec;73(6):1539-1550. doi: 10.1007/s43440-021-00303-6. Epub 2021 Jun 27. PMID: 34176080; PMCID: PMC8236094.
- Zhang, H., Zang, C., Xu, Z. et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 29, 226–235 (2023).
- Peter RS, Nieters A, Kräusslich HG, Brockmann SO, Göpel S, Kindle G, Merle U, Steinacker JM, Rothenbacher D, Kern WV; EPILOC Phase 1 Study Group. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022 Oct 13;379:e071050. doi: 10.1136/bmj-2022-071050. PMID: 36229057; PMCID: PMC9557001.
- Reese JT et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023 Jan;87:104413. doi: 10.1016/j.ebiom.2022.104413. Epub 2022 Dec 21. PMID: 36563487; PMCID: PMC9769411.
Dr Michael Osiecki
PhD, BE(Chemical), BBiotech (Hons)
Dr Osiecki is the Managing Director of Bio Concepts and the second generation of Osiecki biochemists. With scientific prowess and a passion for the industry, Dr Osiecki is an industry influencer and thought leader with a vision of making scientific data-driven complementary medicine an integral part of medicine. Dr…View More